EHA / 13th Congress / Program overview per day / Saturday Program

Saturday Program

SIMULTANEOUS SESSIONS
08:00 – 09:15, Auditorium 1

NON-HODGKIN'S LYMPHOMA - CLINICAL (AGGRESSIVE)
Chairs: A van Hoof (General Hospital St-Jan, Brugge, Belgium)
M Trneny (Hospital of Charles University, Prague, Czech Republic)

08:00 – 08:15
0397 RANDOMIZED PHASE II TRIAL ON PRIMARY CHEMOTHERAPY (CHT)WITH HIGH-DOSE METHOTREXATE (MTX) ALONE OR ASSOCIATED WITH HIGH-DOSE CYTARABINE (ARAC) FOR PATIENTS (PTS) WITH PRIMARY CNS LYMPHOMA (PCNSL): THE INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG) #20 TRIAL
J.M. Ferreri, M. Foppoli, M. Martelli, G. Pangalis, M. Frezzato, G. Cabras,
A. Fabbri, G. Corazzelli, F. Ilariucci, G. Rossi, R. Soffietti, C. Stelitano,
D. Vallisa, F. Zaja, L. Zoppegno, G. Aondio, G. Avvisati, M. Balzarotti,
A.A. Brandes, J. Fajardo, H. Gomez, A. Guarini, G. Pinotti, L. Rigacci,
C. Uhlmann, M. Ponzoni, M. Reni, E. Zucca, F. Cavalli (San Raffaele H Scientific Institute, Milan, Italy)

08:15 – 08:30
0398 CNS RECURRENCE IN AGGRESSIVE LYMPHOMA TREATED WITH MODERN CHEMOTHERAPY (CHOP-14) WITH OR WITHOUT RITUXIMAB: AN ANALYSIS OF CNS-EVENTS IN ELDERLY PATIENTS TREATED IN THE RICOVER-60 TRIAL OF THE GERMAN HIGH-GRADE NON-HODGKIN’S LYMPHOMA STUDY GROUP (DSHNHL)
N. Schmitz, V. Boehme, S. Zeynalova, E. Lengfelder, M. Reiser,
H. Steinhauer, M. Clemens, C. Nickenig, M. Loeffler, M. Pfreundschuh
(ASKLEPIOS KLINIK St. Georg, Hamburg, Germany)

08:30 – 08:45
0399 RESULTS FROM AN INTERNATIONAL STUDY INVESTIGATING THE EFFICACY AND SAFETY OF LENALIDOMIDE IN RELAPSED OR REFRACTORY AGGRESSIVE NON-HODGKIN’S LYMPHOMA
C. Haioun, C.B. Reeder, J. Polikoff, N.M. Chowhan, I. Esseessee,
R. Greenberg, A. Ervin-Haynes, D. Pietronigro, J.B. Zeldis, T.E. Witzig,
M.S. Czuczman (CHU Henri Mondor, Créteil, France)

08:45 – 09:00
0400 THE HOST PHARMACOGENETIC PROFILE IS AN INDEPENDENTPREDICTOR OF OUTCOME AND TOXICITY IN DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH R-CHOP21
D. Rossi, S. Rasi, S. Franceschetti, D. Capello, A. Castelli, A. Chiappella,
L. De Paoli, A. Ramponi, E. Pogliani, U. Vitolo, A. Conconi, G. Gaidano
(Division of Hematology, Amedeo Avogadro University, Novara, Italy)

09:00 – 09:15
0401 PRIMARY DIFFUSE LARGE B-CELL LYMPHOMA OF THE TESTIS: IMPROVED OUTCOME WITH RITUXIMAB-CHOP WITH CNS AND CONTRALATERAL TESTIS PROPHYLAXIS. FINAL RESULTS OF IELSG 10 STUDY
U. Vitolo, E. Zucca, A. Chiappella, M. Martelli, M. Balzarotti, G. Benevolo,
P. De Masi, A. Filippi, M.K. Gospodarowicz, A. Lopez-Guillermo, G. Martinelli,
F. Merli, T. Perrone, P. Pregno, A.H. Sarris, S. Storti, F. Cavalli (On the
behalf of IELSG and IIL, Hematology, San Giovanni Battista Hospital,Torino, Italy)

SIMULTANEOUS SESSIONS
08:00 – 09:15, Hall A3

CHRONIC MYELOID LEUKEMIA – CLINICAL I
Chairs: R Hehlmann (Universität Heidelberg, Heidelberg, Germany)
B Huntly (University of Cambridge, Cambridge, United Kingdom)

08:00 – 08:15
0402 FIRST REPORT OF THE TOPS STUDY: A RANDOMIZED PHASE III TRIAL OF 400MG VS 800MG IMATINIB IN PATIENTS WITH NEWLY DIAGNOSED, PREVIOUSLY UNTREATED CML IN CHRONIC PHASE USING MOLECULAR ENDPOINTS
J.G. Cortes, M. Baccarani, F. Guilhot, B.J. Druker, R. Yu, M. Rudoltz,
T. Krahnke, T. Hughes (The University of Texas, Houston, USA)

08:15 – 08:30
0403 BOSUTINIB (SKI-606) SHOWS HIGH TOLERABILITY AND CLINICAL >ACTIVITY IN PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE LEUKEMIAS
C. Gambacorti-Passerini, J. Cortes, H. Kantarjian, D. Kim, A. Turkina,
T. Fischer, F. Cervantes, S. Agarwal, B. Hewes, T.H. Brummendorf
(University Milano-Bicocca, Monza, Italy)

08:30 – 08:45
0404 NILOTINIB 800 MG DAILY AS FIRST LINE TREATMENT OF CHRONIC MYELOID LEUKEMIA IN EARLY CHRONIC PHASE: RESULTS OF A PHASE 2 TRIAL OF THE GIMEMA CML WORKING PARTY
G. Rosti, F. Castagnetti, F. Palandri, M. Breccia, L. Levato, A. Capucci,
M. Tiribelli, G. Alimena, F. Stagno, M. Rondoni, D. Alberti, G. Marzocchi,
S. Luatti, M. Amabile, A. Poerio, G. Martinelli, F. Pane, G. Saglio,
M. Baccarani (Institute of Hematology "Seràgnoli", Bologna, Italy)

08:45 – 09:00
0405 A PROSPECTIVE RANDOMIZED STUDY OF IMATINIB 400 MG VS 800 MG AS A FRONTLINE THERAPY IN SOKAL HIGH RISK (HR) PH-POS CHRONIC MYELOID LEUKEMIA (CML) PATIENTS
M. Baccarani, I. Haznedaroglu, K. Porkka, F. Castagnetti, D. Alberti,
G. Alimena, M. Amabile, H. Bostrom, H. Hjorth-Hansen, V. Kairisto,
G. Martinelli, J. Nielsen, F. Palandri, F. Pane, G. Rege-Cambrin, D. Russo,
G. Saglio, G. Specchia, N. Testoni, O. Weiss-Bjerrum, G. Rosti,
B. Simonsson (Institute of Hematology "Seragnoli", Bologna, Italy)

09:00 – 09:15
0406 HIGH DOSES OF IMATINIB MESYLATE (800MG/DAY) SIGNIFICANTLY IMPROVE RATES OF MAJOR AND COMPLETE CYTOGENETIC REMISSIONS (MCR, CCR) - RESULTS FROM THE FIRST PLANNED INTERIM ANALYSIS OF A MULTICENTER, RANDOMISED, 2-ARM - PHASE III STUDY COMPARING IMATINIB STANDARD DOSE (400 MG/DAY) WITH IMATINIB HIGH DOSES
A.P. Andreas, D.W. Wolf, D.F. Fong, T. Lion, I. Dyagil, Z. Masliak,
D. Boskovic, G. Laimonas, S. Lejniece, S. Goranov, L. Gercheva,
A. Stojanovic, D. Peytchev, N. Tzvetkov, R. Griniute, R. Oucheva,
G. Fincato, H. Ulmer, G.G. Gastl (Central European Leukemia Study
Group (CELSG), Innsbruck and Hospital BHS Linz, Linz, Austria)

SIMULTANEOUS SESSIONS
08:00 – 09:15, Auditorium 2

CHRONIC LYMPHOCYTIC LEUKEMIA – BIOLOGY AND CLINICAL
Chairs: F Cymbalista (Hôpital Saint-Louis, Paris, France)
J Gribben (Centre for Medical Oncology, London, United Kingdom)

08:00 – 08:15
0407 SHORT TELOMERE LENGTH IS AN INDEPENDENT PREDICTOR OF SURVIVAL, PROGRESSION, RICHTER'S SYNDROME TRANSFORMATION AND RECURRENT INFECTIONS: AN ANALYSIS ON 421 CLL PATIENTS INCLUDING BLINDED VALIDATION ON 230 CASES
D. Rossi, C. Lobetti Bodoni, E. Genuardi, L. Monitillo, M. Cerri,
C. Deambrogi, D. Drandi, I. Ricca, A. Rocci, M. Boi, S. Ferrero,
D. Capello, L. De Paoli, L. Bergui, P. Omedè, M. Massaia, M. Boccadoro,
G. Gaidano, M. Ladetto (Amedeo Avogadro University of Easten Piedmont, Novara, Italy)

08:15 – 08:30
0408 THE MOST FREQUENT T(1419)(Q32;Q13)-POSITIVE B-CELL MALIGNANCY CORRESPONDS TO AN AGGRESSIVE SUBGROUP OF ATYPICAL CHRONIC LYMPHOCYTIC LEUKEMIA
F. Nguyen-Khac, E. Chapiro, I. Radford-Weiss, C. Bastard, I. Luquet,
C. Lefebvre, E. Callet-Bauchu, D. Leroux, P. Talmant, M.-J. Mozzicconacci,
F. Mugneret, S. Struski, S. Raynaud, J. Andrieux, C. Barin, M. Jotterand,
H. Mossafa, S. Ramond, C. Terré, E. Lippert, F. Berger, P. Felman,
H. Merle-Béral, O.A. Bernard, F. Davi, R. Berger (Pitie-Salpetriere,Paris, France)

08:30 – 08:45
0409 CD49D EXPRESSION IS AN INDEPENDENT RISK FACTOR OF PROGRESSIVE DISEASE IN EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA
D. Rossi, A. Zucchetto, F.M. Rossi, D. Capello, M. Cerri, C. Deambrogi,
S. Cresta, S. Rasi, L. De Paoli, C. Lobetti Bodoni, P. Bulian, G. Del Poeta,
M. Ladetto, V. Gattei, G. Gaidano (Division of Hematology, Amedeo
Avogadro University, Novara, Italy)

08:45 – 09:00
0410 TP53 MUTATIONS AND DEL17P13 PREDICT SIMILAR OUTCOME AND CHEMOREFRACTORINESS IN CHRONIC LYMPHOCYTIC LEUKEMIA
M. Cerri, C. Deambrogi, D. Capello, S. Cresta, S. Rasi, E. Sozzi,
L. De Paoli, V. Gattei, F. Forconi, G. Gaidano, D. Rossi (Division of
Hematology, Amedeo Avogadro University, Novara, Italy)

09:00 – 09:15
0411 CLINICAL AND BIOLOGICAL CHARACTERIZATION OF CIRCULATING ENDOTHELIAL CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA
G.M. Rigolin, R. Maffei, L. Rizzotto, M. Ciccone, O. Sofritti, G. Daghia,
F. Cibien, F. Cavazzini, R. Marasca, G. Castoldi, A. Cuneo (Hematology -
University of Ferrara, Ferrara, Italy)

SIMULTANEOUS SESSIONS
08:00 – 09:15, Hall C1

STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA
Chairs: H Lokhorst (University Medical Center Utrecht, Utrecht,
The Netherlands)
R Schlenk (University of Ulm, Ulm, Germany)

08:00 – 08:15
0412 NON-MYELOABLATIVE ALLOGRAFTING FOR NEWLY DIAGNOSED MYELOMA: FINAL RESULTS OF A PROSPECTIVE PHASE II STUDY BY GRUPPO ITALIANO TRAPIANTO MIDOLLO OSSEO
L. Giaccone, R. Sorasio, F. Patriarca, D. Mattei, B. Allione, F. Carnevale
Schianca, A. Rambaldi, M. Casini, V. Montefusco, M. Parma, P. Bavaro,
F. Onida, A. Busca, L. Castagna, A.P. Iori, E. Benedetti, N. Mordini,
M. Rotta, F. Fiore, A. Filippi, A.P. Palumbo, I. Resta, M. Festuccia,
M. Aglietta, A. Levis, R. Foà, P. Di Bartolomeo, E. Pogliani,
G. Lambertenghi-Deliliers, M. Falda, M. Petrini, P. Corradini, R. Fanin,
I. Baldi, U. Ricardi, B. Bruno, M. Boccadoro (Divisione di Ematologia
dell' Università di Torino, AOU San Giovanni Battista, Torino, Italy)

08:15 – 08:30
0413 REDUCED INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION (RIC ALLO-SCT) FOR PATIENTS WITH HIGH-RISK MULTIPLE MYELOMA (MM): A SURVEY FROM THE SOCIETE FRANCAISE DE GREFFE DE MOELLE ET DE THERAPIE CELLULAIRE
M. Mohty, M. Mohty, L. Quoc-Hung, F. Nicolini, F. Garban, H. Esperou,
M. Attal, N. Milpied, B. Lioure, P. Bordigoni, I . Yakoub-Agha,
J.H. Bourhis, B. Rio, E. Deconinck, M. Renaud, J.L. Harousseau,
D. Blaise, M. Michallet (CHU de Nantes, Nantes, France)

08:30 – 08:45
0414 UPDATED ANALYSIS OF ALLOGENEIC HSCT AFTER RIC FOR HEMATOLOGICAL MALIGNANCIES FROM THE SOCIÉTÉ FRANÇAISE DE GREFFE DE MOELLE OSSEUSE ET DE THÉRAPIE CELLULAIRE (SFGM-TC) REGISTRY
M. Michallet, M. Michallet, Q. Le, M. Mohty, M. Sobh, F.E. Nicolini,
J.-M. Boiron, H. Espérou, M. Attal, N. Milpied, B. Lioure, P. Bordigoni,
I. Yackoub-Agha, J. Bourhis, B. Rio, E. Deconninck, M. Renaud,
N. Raus, D. Blaise (Hôpital Edouard Herriot, Lyon, France)

08:45 – 09:00
0415 A PROSPECTIVE PETHEMA STUDY OF TANDEM AUTOLOGOUS TRANSPLANTATION VERSUS AUTOGRAFT FOLLOWED BY REDUCED-INTENSITY CONDITIONING ALLOGENEIC TRANSPLANTATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA
J. Blade, L. Rosiñol, J.A. Pérez-Simón, A. Sureda, J. De la Rubia,
F. De Arriba, J.J. Lahuerta, J.D. González, R. Martínez-Martínez,
B. Hernández-Ruíz, J. García-Frade, D. Carrera, A. León, M. Hernández,
P. Fernández-Abellán, J.M. Bergua, J. San Miguel (Hospital Clinic,
Barcelona, Spain)

09:00 – 09:15
0416 THE HEMATOPOIETIC CELL TRANSPLANTATION-SPECIFIC COMORBIDITY INDEX (HCT-CI) PREDICTS SURVIVAL AND NON-RELAPSE MORTALITY IN LYMPHOMA AND MYELOMA PATIENTS RECEIVING RIC ALLOGRAFT
L. Farina, B. Bruno, F. Patriarca, F. Spina, R. Sorasio, M. Morelli,
R. Fanin, M. Boccadoro, P. Corradini (Istituto Nazionale Tumori,
University of Milano, Milano, Italy)

SIMULTANEOUS SESSIONS
08:00 – 09:15, Hall C2

CYTOGENETICS AND MOLECULAR DIAGNOSTICS
Chairs: N Cross (University of Southampton, Southampton, United Kingdom)
B Schlegelberger (Hannover Medical School, Hannover, Germany)

08:00 – 08:15
0417 DIFFERENCES IN CYTO- AND MOLECULAR GENETIC ABERRATIONS BETWEEN YOUNG (< 2YR) AND OLDER CHILDREN WITH ACUTE MYELOID LEUKEMIA
B.V. Balgobind, I.H.I.M. Hollink, D. Reinhardt, J. Bradtke,
A. Teigler-Schlegel, A.R. Von Bergh, J. Cloos, G.J.L. Kaspers,
E. van Wering, Z. Zemanova, J. Stary, J. Cayuela, A. Baruchel,
M.M. van den Heuvel-Eibrink, C.M. Zwaan (Erasmus MC - Sophia's
Children Hospital, Rotterdam, The Netherlands)

08:15 – 08:30
0418 COMPREHENSIVE MOLECULAR ANALYSES OF TP53 GENE ALTERATIONS IN ACUTE MYELOID LEUKEMIA WITH COMPLEX KARYOTYPE
F.G. Rücker, L. Bullinger, C.-M. Kugler, S. Miller, H.A. Kestler, P. Lichter,
H. Döhner, K. Döhner (University of Ulm, Ulm, Germany)

08:30 – 08:45
0419 DIAGNOSTIC AND PROGNOSTIC IMPACT OF GENE EXPRESSION PROFILING BASED MOLECULAR MARKER PREDICTION IN CYTOGENETICALLY NORMAL AML
L. Bullinger, T. Hielscher, C. Stirner, R. Kranz, Y.H. Kim, S. Fröhling,
R.F. Schlenk, A. Benner, K. Döhner, J.R. Pollack, H. Döhner (University
of Ulm, Ulm, Germany)

08:45 – 09:00
0420 IMPROVED DETECTION AND MOLECULAR MONITORING OF FIP1L1-PDGFRA BY ANALYSIS OF PATIENT-SPECIFIC GENOMIC DNA FUSION JUNCTIONS
C. Score, C. Walz, J.V. Jovanovic, A.V. Jones, K. Waghorn,
C.E. Hidalgo-Curtis, D. Grimwade, F.H. Grand, A. Reiter, N.C.P. Cross
(Leukaemia Research, Salisbury, United Kingdom)

09:00 – 09:15
0421 EARLY ASSESSMENT OF MINIMAL RESIDUAL DISEASE (MRD) BY OPTIMIZED REAL-TIME QUANTITATIVE PCR (RQ-PCR) ASSAY FOR DETECTION OF WT1 TRANSCRIPTS PROVIDES AN INDEPENDENT PREDICTOR OF DISEASE RELAPSE IN ACUTE MYELOID LEUKEMIA: A EUROPEAN LEUKEMIANET (ELN) STUDY
D. Cilloni, A. Renneville, F. Hermitte, R.K. Hills, S. Daly, J. Jovanovic,
E. Gottardi, M. Fava, S. Schnittger, T. Weiss, B. Izzo, J. Nomdedeu,
A. van der Heijden, B. van der Reijden, V. van der Velden, P. Rohon,
H. Ommen, J. Polak, J. Jansen, C. Preudhomme, G. Saglio,
D. Grimwade (University of Turin, Turin, Italy)

SIMULTANEOUS SESSIONS
08:00 – 09:15, Hall C3

GENE THERAPY, CELLULAR IMMUNOTHERAPY AND VACCINATION
Chairs: F Falkenburg (Leiden University Medical Center, Leiden, The Netherlands)
E Morris (University College London, London, United Kingdom)

08:00 – 08:15
0422 LENTIVIRAL GENE THERAPY OF HEMATOPOIETIC STEM CELLS RESULTS IN PHENOTYPE CORRECTION IN A MOUSE MODEL OF POMPE DISEASE
M. Stok, N. van Til, F.S.F. Aerts Kaya, T.P. Visser, M. Kroos,
M. de Waard, E. Jacobs, M. Willart, P. van der Wegen, B. Scholte,
B. Lambrecht, D. Duncker, A. van der Ploeg, A. Reuser, M. Verstegen,
G. Wagemaker (Erasmus MC, Rotterdam, The Netherlands)

08:15 – 08:30
0423 AN ORIGINAL GENE THERAPY STRATEGY OF HEMOPHILIA B USING LENTIVIRALLY MODIFIED HEMATOPOIETIC STEM CELLS
M. Cambot, C. Lavenu-Bombled, J. Cossonière, J.P. Rosa,
A. Dubart-Kupperschmitt (INSERM, Le Kremlin-bicêtre Cedex, France)

08:30 – 08:45
0424 REDIRECTING T-CELLS AGAINST CANCER CELLS BY TRANSFER OF BROADLY TUMOR REACTIVE GAMMA-DELTA-T-CELL RECEPTORS
J.H.E. Kuball, V. Marcu-Malina, M. Theobald (UMC Utrecht, Utrecht,
The Netherlands)

08:45 – 09:00
0425 REGULATORY T CELLS ARE RESISTANT TO PROTEOSOME INHIBITOR MEDIATED APOPTOSIS AND CAN BE EXPANDED IN VITRO IN UPON CULTURE WITH BORTEZOMIB
J.A. Pérez-Simón, B. Blanco, L.I. Sánchez-Abarca, M. Díez-Campelo,
S. Tabera, P. Hernández-Campo, S. Gutierrez-Cosio, C. Rodriguez-
Serrano, F. Sanchez-Guijo, C. Cañizo, J.F. San Miguel (Hospital
Universitario, Salamanca, Spain)

09:00 – 09:15
0426 VACCINATION OF ACUTE MYELOID LEUKEMIA PATIENTS WITH DENDRITIC CELLS ELECTROPORATED WITH MRNA ENCODING THE WILMS TUMOR PROTEIN WT1: A PHASE I/II TRIAL
L.R. Van de Velde, A. Van Driessche, N. Cools, G. Nijs, B. Stein,
K. Vermeulen, K. Pieters, I. Vrelust, A.P. Gadisseur, W.A. Schroyens,
I.J. De Vries, D.A. Price, Z.N. Berneman, V.F. Van Tendeloo (Antwerp
University Hospital, Edegem, Belgium)

SIMULTANEOUS SESSIONS
08:00 – 09:15, Hall C4

VASCULAR BIOLOGY, BLEEDING DISORDERS AND TRANSFUSION MEDICINE
Chairs: M Marchetti (Ospedali Riuniti, Bergamo, Italy)
M Cattaneo (Ospedale San Paolo-Universit, Milan, Italy)

08:00 – 08:15
0427 ANGIOGENESIS AND VEGF-/RECEPTOR EXPRESSION IN MYELOPROLIFERATIVE DISEASES: CORRELATION WITH CLINICAL PARAMETERS AND JAK2-V617F MUTATIONAL STATUS
M. Medinger, A. Gratwohl, A. Theocharides, A. Buser, D. Heim, R. Skoda,
S. Dirnhofer, A. Tichelli, A. Tzankov (University Hospital, Basel, Switzerland)

08:15 – 08:30
0428 MANAGEMENT OF REPRODUCTIVE EVENTS IN FEMALES WITH GAUCHER DISEASE
A. Zimran, N. Belmatoug, S. Granovosky-Grisaru, R. Heitner, D.A. Hughes,
P. Kaplan, V. Malinova, E. Mengel, E. Morris, M. Mrsic, S. vom Dahl
(Shaare Zedek Medical Centre, Jerusalem, Israel)

08:30 – 08:45
0429 HEALTHY BLOOD DONORS WITH A POSITIVE COOMBS TEST: NATURAL ANTI-C3 AND FRAMEWORK-SPECIFIC ANTIBODIES TOGETHER INHIBIT COMPLEMENT DEPENDENT PHAGOCYTOSIS OF SENESCENT RED BLOOD CELLS
H.U. Lutz, B.M. Frey, P. Stammler, A. Siderow, M. Kradolfer, V. Alaia
(ETH Zurich, Zurich, Switzerland)

08:45 – 09:00
0430 HOME BLOOD AND PLATELET TRANSFUSIONS AS PART OF A DOMICILIARY PROGRAM OF SUPPORTIVE CARE IN PATIENTS WITH BLOOD MALIGNANCIES: AN ITALIAN SINGLE-CENTRE EXPERIENCE
P. Alfieri (Division of Haematology, Modena, Italy)
Favale E, De Palma M, Torelli G

09:00 – 09:15
0431 THE BURDEN OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) IN ADULTS: RESULTS OF A DELPHI PANEL OF 32 EUROPEAN CLINICAL EXPERTS
F.G. Rodeghiero, M. Michel, J. Besalduch, D. Provan, M. Rummel,
M. Aivado, K. Grotzinger, N.L. Papo, S. Stamenitis, N. Höbel (Ospedale
S Bartolo di Vicenza, Vicenza, Italy)

SIMULTANEOUS SESSIONS
10:30 – 11:45, Hall A3

MYELOPROLIFERATIVE DISORDERS
Chairs: J-J Kiladjian (Hôpital Avicenne, Paris, France)
M-F McMullin (Queen's University of Belfast, Belfast, United Kingdom)

10:30 – 10:45
0442 FAMILIAL ERYTHROCYTOSIS ASSOCIATED WITH A MUTATIONAL HOTSPOT IN THE HIF2A GENE
M.J. Percy, P.A. Beer, G. Campbell, A.W. Dekker, A.R. Green, D. Oscier,
M.G. Rainey, R. van Wijk, M. Wood, T.R.J. Lappin, M.F. McMullin,
F.S. Lee (Belfast City Hospital, Belfast, United Kingdom)

10:45 – 11:00
0443 THE ETV6-PDGFR? AND FIP1L1-PDGFR? FUSION PROTEINS ESCAPE UBIQUITINATION AND DEGRADATION
F. Toffalini, A. Kallin, L. Michaux, P. Vandenberghe, P. Pierre, J. Cools,
J.B. Demoulin (Université Catholique de Louvain, Brussels, Belgium)

11:00 – 11:15
0444 THE SELECTIVE JANUS KINASE (JAK) INHIBITOR, INCB018424, SHOWS EFFICACY IN A PHASE I/II TRIAL IN PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF) AND POST POLYCYTHEMIA VERA/ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (POST-PV/ET MF)
S. Verstovsek, H. Kantarjian, A. Pardanani, D. Thomas, J. Cortes,
R. Mesa, W. Hogan, J. Redman, R. Levy, K. Vaddi, J. Fridman, A. Tefferi
(M.D. Anderson Cancer Center, Houston, Texas, USA)

11:15 – 11:30
0445 THE CLINICAL PHENOTYPE OF PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA HARBORING MPL 515W>L/K MUTATION
E. Antonioli, A. Pancrazzi, P. Guglielmelli, A. Bosi, G. Barosi,
M. Ruggeri, G. Specchia, F. Lo Coco, T. Barbui, A.M. Vannucchi
(University of Florence, Firenze, Italy)

11:30 – 11:45
0446 PEGYLATED INTERFERON-ALFA-2A INDUCES COMPLETE HEMATOLOGICAL AND MOLECULAR RESPONSES WITH LOW TOXICITY IN POLYCYTHEMIA VERA: RESULTS OF THE PV-NORD PVN1 STUDY
J.J. Kiladjian, B. Cassinat, P. Turlure, N. Cambier, M. Roussel, S. Bellucci,
S. Chevret, B. Grandchamp, C. Chomienne, P. Fenaux (AP-HP, Hôpital
Avicenne, Bobigny, France)

SIMULTANEOUS SESSIONS
10:30 – 11:45, Auditorium 2

INFECTIOUS DISEASES, SUPPORTIVE CARE
Chairs: C Brunstein (University of Minnesota Medical School, Minneapolis, USA)
P Ljungman (University Hospital, Huddinge, Sweden)

10:30 – 10:45
0447 INCIDENCE OF INFECTIONS IN SPLENECTOMISED PATIENTS AND GENERAL POPULATION COMPARISONS: NATIONWIDE COHORT STUDY IN DENMARK
W.M. Schoonen, R.W. Thomsen, D. Körmendiné Farkas, A. Riis,
J.P. Fryzek, H.T. Sørensen (Amgen, Uxbridge, Middlesex, United Kingdom)

10:45 – 11:00
0448 IMPACT OF PRIOR INVASIVE PULMONARY ASPERGILLOSIS (IPA) ON OUTCOME IN PATIENTS RECEIVING REDUCED INTENSITY CONDITIONING (RIC) ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-SCT)
J. El cheikh, L. Wang, C. Faucher, S. Furst, P. Berger, D. Blaise
(Paoli Calmettes, Marseille, France)

11:00 – 11:15
0449 HBV REVERSE SEROCONVERSION AND INTERVENTION WITH VACCINATION AFTER ALLOGENEIC HSCT IN PATIENTS WITH PREVIOUS HBV INFECTION
M. Onozawa, S. Hashino, R. Morita, K. Kahata, T. Kondo, J. Tanaka,
M. Imamura, M. Asaka (Hokkaido University Hospital, Sapporo, Japan)

11:15 – 11:30
0450 CLINICAL VALUE OF SCREENING DETECTION OF 1,3-BETA-D GLUCAN (BG) FOR EARLY DIAGNOSIS OF INVASIVE FUNGAL INFECTIONS (IFI) IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES – RESULTS OF A PROSPECTIVE STUDY
Z. Racil, I. Kocmanova, B. Weinbergerova, J. Winterova, M. Lengerova,
J. Mayer (University Hospital Brno and Masaryk University, Brno,
Czech Republic)

11:30 – 11:45
0451 HIGH-DOSE ACICLOVIR FAILS TO PREVENT CYTOMEGALOVIRUS INFECTION AND DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
N. Duncan, D. Stocken, H. Osman, J. Ward, P. Moss, M. Cook,
C. Craddock (University Hospital Birmingham NHS Foundation Trust,
Birmingham, United Kingdom)

SIMULTANEOUS SESSIONS
10:30 – 11:45, Hall C1

ACUTE LYMPHOBLASTIC LEUKEMIA – BIOLOGY
Chairs: R Panzer-Grümayer (Children's Cancer Research Institute,
Vienna, Austria)
A Rambaldi (Ospedali Riuniti, Bergamo, Italy)

10:30 – 10:45
0452 TIME TO LEUKAEMIA (TTL) ASSESSED IN NOD/SCID MICE TRANSPLANTED WITH PRIMARY ALL LEUKAEMIA CELLS DETERMINES EARLY RELAPSE IN PATIENTS AND IS IDENTIFIED BY A SPECIFIC GENE SIGNATURE
L. Meyer, S.M. Eckhoff, M. Queudeville, M. Zimmermann,
A. Schrauder, G. Lahr, K. Holzmann, M. Schrappe, K. Stahnke,
K.-M. Debatin (University of Ulm, Ulm, Germany)

10:45 – 11:00
0453 UNIQUE DNA METHYLATION PATTERNS SEPARATE DISTINCT SUBTYPES OF MLL REARRANGED INFANT ALL
D.J.P.M. Stumpel, P. Schneider, R.X. Menezes, E.H.J. van Roon,
T.C.M. Peters, J.M. Boer, R. Pieters, R.W. Stam (Erasmus MC
Rotterdam - Sophia Children's Hospital, the Netherlands, Rotterdam,
The Netherlands)

11:00 – 11:15
0454 HIGH-RESOLUTION GENOMIC PROFILING OF PH-POSITIVE ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL) IDENTIFIED RECURRENT COPY NUMBER ANOMALIES IN GENES REGULATING THE CELL CYCLE AND THE B-CELL DIFFERENTIATION
I. Iacobucci, E. Ottaviani, A. Astolfi, T. Storlazzi, N. Testoni, I. Luciana,
A. Lonetti, S. Soverini, S. Paolini, P.P. Piccaluga, C. Papayannidis,
P. Giannoulia, F. De Rosa, D. Cilloni, F. Messa, A. Pession, F. Pane,
A. Vitale, S. Chiaretti, R. Foà, M. Baccarani, G. Martinelli (Department
of Hematology/Oncology "Seràgnoli", Bologna, Italy)

11:15 – 11:30
0455 MONOALLELIC LOSS AND FREQUENT MUTATION OF THE SECOND ALLELE OF PAX5 ARE GENETIC HALLMARKS OF DIC(920) CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
S. Strehl, K. Nebral, M. König, D. Krehan (CCRI, Children's Cancer
Research Institute, Vienna, Austria)

11:30 – 11:45
0456 IDENTIFICATION OF CANCER STEM CELLS IN B-CELL LYMPHOID HEMATOLOGIC MALIGNANCIES
H. Nishida (The Institute of Medical Science, The University of Tokyo,
Tokyo, Japan)

SIMULTANEOUS SESSIONS
10:30 – 11:45, Hall C2

ACUTE MYELOID LEUKEMIA - BIOLOGY I
Chairs: D Grimwade (King's College London School of Medicine, London,
United Kingdom)
S Schnittger (MLL Munich Leukemia Laboratory, Munich, Germany)

10:30 – 10:45
0457 WILMS’ TUMOR 1 (WT1) GENE MUTATIONS IN CHILDHOOD ACUTE MYELOID LEUKEMIA: CHARACTERISTICS, PROGNOSTIC VALUE AND CONSEQUENCES FOR MRD DETECTION
I.H.I.M. Hollink, M.M. van den Heuvel-Eibrink, M. Zimmermann,
T.J.C.M. Arentsen-Peters, M. Alders, G.J. Kaspers, J. Stary,
A. Baruchel, S.S. De Graaf, U. Creutzig, D. Reinhardt, R. Pieters,
C.M. Zwaan (Erasmus MC – Sophia Children's Hospital, Rotterdam,
The Netherlands)

10:45 – 11:00
0458 MIR-125B: RELEVANCE IN CHILDHOOD ACUTE MEGAKARYOBLASTIC LEUKEMIAS
K. Boehmer, J.H. Klusmann, D. Reinhardt (Hannover Medical School,
Hannover, Germany)

11:00 – 11:15
0459 GENOME-WIDE SNP ANALYSIS IDENTIFIES GENOMIC ABNORMALITIES IN ACUTE MYELOID LEUKEMIA WITH NORMAL KARYOTYPE
J. Kronke, L. Bullinger, C. Schön, K. Urlbauer, S. Miller, C. Senger,
K. Holzmann, R. Schlenk, K. Döhner, H. Döhner (University of Ulm,
Ulm, Germany)

11:15 – 11:30
0460 THE LEUKEMOGENIC TRANSCRIPTION FACTOR ERG COLLABORATES WITH GATA1S TO IMMORTALIZE MEGAKAROCYTIC PRECURSORS: A MOUSE MODEL FOR THE PATHOGENESIS OF SPORADIC AND DOWN SYNDROME ASSOCIATED ACUTE MEGAKARYOBLASTIC LEUKEMIAS
S. Izraeli, S. Salek-Ardakani, J. De Boer, N.J. Sebire, L. Rainis, S. Lee,
O. Williams, S. Izraeli, H.J.M. Brady (Sheba medical center, Ramat Gan,
Israel)

11:30 – 11:45
0461 IDENTIFICATION OF THREE TYROSINE RESIDUES OF IMPORTANCE FOR SURVIVAL SIGNALING OF FLT3 ITD THROUGH GAB2
K. Masson, T. Liu, J. Sun, L. Rönnstrand (Lund University, Malmö, Sweden)

SIMULTANEOUS SESSIONS
10:30 – 11:45, Hall C3

ANEMIA AND BONE MARROW FAILURE
Chairs: N Borregaard (Rigshospitalet, Copenhagen, Denmark)
J Soulier (Hôpital Saint-Louis, Paris, France)

10:30 – 10:45
0462 OPPOSING EFFECTS OF PROTEIN KINASE A AND C CAUSES DIFFERENTIAL PHOSPHATIDYLSERINE EXPOSURE IN A CD47 RECEPTOR MEDIATED ERYTHROCYTE APOPTOTIC PATHWAY
P. Jeremy, F. Gilsanz, J. Delaunay, N. Avent (University of the West of
England, Bristol, United Kingdom)

10:45 – 11:00
0463 CHARACTERISATION OF TINF2 MUTATIONS IN A LARGE COHORT OF PATIENTS WITH DYSKERATOSIS CONGENITA AND RELATED BONE MARROW FAILURE SYNDROMES
A. Walne, T. Vulliamy, R. Beswick, M. Kirwan, I. Dokal (Institute of cell
and molecular sciences, London, United Kingdom)

11:00 – 11:15
0464 EVIDENCE OF A SUB-CLINICAL LYMPHOPROLIFERATIVE DISEASE IN PATIENTS WITH “IDIOPATHIC” AUTOIMMUNE HEMOLYTIC ANEMIA
F.R. Mauro, M.S. De Propris, I. Del Giudice, D. Armiento, S. Coluzzi,
I. Della Starza, M.C. De Nicolo', M.C. Arista, L. Quattrocchi, G. Girelli,
A. Guarini, R. Foa' (University "La Sapienza", Rome, Italy)

11:15 – 11:30
0465 DOUBLE CORD BLOOD TRANSPLANTATION FOR PATIENTS WITH INHERITED AND ACQUIRED BONE MARROW FAILURE SYNDROMES
A. Ruggeri, R. Peffault de Latour, V. Rocha, C.A. Rodrigues, M. Robin,
J. Larghero, R. Traineau, P. Ribaud, C. Ferry, A. Devergie, E. Gluckman,
G. Socié (Bone Marrow Transplantation unit, Paris, France)

11:30 – 11:45
0466 EFFECTS OF STAT5A PHOSPHORYLATION ON PROLIFERATION AND DIFFERENTIATION OF MYELOID HEMATOPOIETIC PROGENITORS IN HEALTHY INDIVIDUALS AND IN PATIENTS WITH SEVERE CONGENITAL NEUTROPENIA
J. Skokowa, K. Gupta, A. Müller Brechlin, K. Welte (Hannover Medical
School, Hannover, Germany)

SIMULTANEOUS SESSIONS
10:30 – 11:45, Hall C4

HODGKIN'S LYMPHOMA
Chairs: P Brice (Hôpital Saint Louis, Paris, France)
J Walewski (MSCM Institute and Cancer Centre, Warsaw, Poland)

10:30 – 10:45
0467 FDG-PET FOR ASSESSMENT OF RESIDUAL TISSUE AFTER COMPLETION OF CHEMOTHERAPY IN HODGKIN LYMPHOMA REPORT ON THE 2ND INTERIM ANALYSIS OF THE PET INVESTIGATION IN THE TRIAL HD15 OF THE GHSG
M. Fuchs, H. Haverkamp, M. Dietlein, V. Diehl, A. Engert, C. Kobe
(University Hospital of Cologne, Cologne, Germany)

10:45 – 11:00
0468 ALLOGENEIC STEM CELL TRANSPLANTATION AFTER A RIC REGIMEN PROLONGS THE SURVIVAL IN PATIENTS WITH HODGKIN LYMPHOMA (HL) RELAPSED AFTER HIGH-DOSE CHEMOTHERAPY: A RETROSPECTIVE STUDY BASED ON DONOR AVAILABILITY
L. Castagna, B. Sarina, F. Benedetti, G. Milone, P. Patriarca, S. Viviani,
M. Malagola, S. Ferrari, G. Sorasio, L. Farina, E. Todisco, L. Giordano,
P. Corradini (Istituto Clinico Humanitas, Rozzano, Italy)

11:00 – 11:15
0469 EARLY INTERIM FDG-PET IN ADVANCED-STAGE HODGKIN LYMPHOMA (HL). LONG-TERM RESULTS OF THE ITALIANDANISH COOPERATIVE STUDY
A. Gallamini, M. Hutchings, L. Rigacci, L. Specht, F. Merli, M. Hansen,
C. Patti, A. Loft, F. Di Raimondo, F. D'Amore, A. Biggi, P. Pregno,
C. Stelitano, R. Sancetta, L. Trentin, S. Luminari, E. Iannitto, S. Viviani,
I. Pierri, P. Torchio, A. Levis (Az. Ospedaliera S. Croce e Carle, Cuneo, Italy)

11:15 – 11:30
0470 CNS HODGKIN LYMPHOMA: AN INTERNATIONAL PRIMARY CNS LYMPHOMA COLLABORATIVE GROUP (IPCG) REPORT OF 18 CASES
R. Gerstner, L.E. Abrey, D. Schiff, A.J.M. Ferreri, A. Lister, S. Montoto,
R. Tsang, E. Thiel, F. Graus, D. Behringer, G. Illerhaus, S. Weaver,
P. Wen, N.L. Harris, T.T. Batchelor (Massachusetts General Hospital,
Boston, Ma, United States of America)

SIMULTANEOUS SESSIONS
10:30 – 11:45, Hall A1

NON-HODGKIN'S LYMPHOMA – INDOLENT
Chairs: C Buske (Klinikum Großhadern, Munich, Germany)
F Morschhauser (Centre Hospitalier Universitaire, Lille, France)

10:30 – 10:45
0432 PHASE 3 STUDY OF PATIENTS WITH RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA: COMPARISON OF TREATMENT WITH TEMSIROLIMUS VERSUS INVESTIGATOR'S CHOICE THERAPY
E. G. Verhoef, G. Heß, J. Romaguera, R. Herbrecht, M. Crump,
A. Strahs, O. Hanushevsky, F. Binlich, B. Hewes, B. Coiffier (University
Hospital Gasthuisberg, Leuven, Belgium)

10:45 – 11:00
0433 RESULTS FROM THE RANDOMIZED PHASE 3 FIRST-LINE INDOLENT TRIAL (FIT) OF CONSOLIDATION OF FIRST REMISSION WITH 90Y-IBRITUMOMAB TIUXETAN IN ADVANCED FOLLICULAR NON-HODGKIN’S LYMPHOMA (FL)
J.A. Radford, F. Morschhauser, A. Van Hoof, U. Vitolo, P. Soubeyran,
H. Tilly, P.C. Huijgens, A. Kolstad, M. Kunz, A. Hagenbeek (Christie
Hospital, Manchester, United Kingdom)

11:00 – 11:15
0434 BRIEF CHEMOIMMUNOTHERAPY WITH RITUXIMAB (R)-FND +/- R MAINTENANCE AS FIRST LINE TREATMENT IN ADVANCED FOLLICULAR LYMPHOMA (FL) IN ELDERLY: PRELIMINARY ANALYSIS OF A PROSPECTIVE RANDOMIZED TRIAL
U. Vitolo, M. Ladetto, C. Boccomini, E. Gamba, I. Alvarez, L. Baldini,
M. Ceccarelli, A. Chiappella, P. Corradini, A. De Renzo, F. Di Raimondo,
A. Gallamini, A. Guarini, B. Mantoan, M. Martelli, V. Naso, G. Parvis,
M. Petrini, P. Pinto, S. Pozzi, A. Pulsoni, L. Rigacci, C. Tarella, A. Tucci,
F. Zaja, E. Gallo (Intergruppo Italiano linfomi (IIL), Hematology,
S Giovanni Battista, Hospital And University Torino, Italy)

11:15 – 11:30
0435 ROMIDEPSIN INDUCES CLINICALLY SIGNIFICANT AND DURABLE RESPONSES IN RELAPSED OR REFRACTORY CTCL: A NCI INTERNATIONAL, MULTICENTER STUDY
S. Bates, R. Piekarz, R. Frye, S. Allen, M. Craig, L. Geskin, L. Hutchins,
D. Joske, M. Kirschbaum, J. Leonard, M. Prince, C. Reeder, J. Nichols
(National Cancer Institute, Bethesda, USA)

11:30 – 11:45
0436 SUMMARY OF THE CLINICAL BENEFIT OF VORINOSTAT IN RELAPSED/REFRACTORY CTCL
E.A. Olsen, S. Rizvi, J. Garcia-Vargas, C. Sanz-Rodriguez, J. Viscusi,
M. Gates, M. Duvic (Duke University Medical Center, Durham, USA)

SIMULTANEOUS SESSIONS
10:30 – 11:45, Auditorium 1

MULTIPLE MYELOMA: IMPROVING STANDARD THERAPY FOR THE ELDERLY
Chairs: P Sonneveld (Erasmus Medical Center, Rotterdam, The Netherlands)
A Waage (St. Olavs Hospital, Trondheim, Norway)

10:30 – 10:45
0437 A PHASE IB, MULTI-CENTER, OPEN-LABEL, DOSE-ESCALATION STUDY OF ORAL PANOBINOSTAT (LBH589) AND I.V. BORTEZOMIB IN ADULT PATIENTS WITH MULTIPLE MYELOMA (MM)
O. Sezer, M. Kaiser, D. Siegel, I. Prosser, M.V. Mateos, M. Kangas,
M. Jalaluddin, P. Bourquelot, J. Bladé, J. San Miguel, K. Anderson,
J. Bradner (Charité, Berlin, Germany)

10:45 – 11:00
0438 BORTEZOMIB, PEGYLATED-LYPOSOMAL-DOXORUBICIN AND DEXAMETHASONE AS INDUCTION PRIOR TO AUTOLOGOUS TRANSPLANT, FOLLOWED BY LENALIDOMIDE AS MAINTENANCE IN ELDERLY NEWLY DIAGNOSED MYELOMA PATIENTS
A. Palumbo, P. Falco, C. Crippa, V. Montefusco, F. Patriarca, M. Ruggeri,
A. Larocca, F. Cavallo, A.M. Liberati, F. Rossini, N. Giuliani, T. Guglielmelli,
G. Benevolo, C. Cangialosi, T. Caravita, G. Rossi, P. Corradini,
M. Boccadoro (A.O.U. San Giovanni Battista, Torino, Italy)

11:00 – 11:15x
0439 RECOVERY OF RENAL IMPAIRMENT BY BORTEZOMIBDOXORUBICIN-DEXAMETHASONE (BDD) IN MULTIPLE MYELOMA (MM) PATIENTS WITH ACUTE RENAL FAILURE. RESULTS FROM AN ONGOING PHASE II STUDY
P. Ludwig, Z. Adam, R. Greil, F. Keil, N. Zojer, J. Thaler, H. Gisslinger,
A. Lang (Wilhelminenspital, Vienna, Austria)

11:15 – 11:30
0440 MELPHALAN + PREDNISONE VERSUS MELPHALAN +PREDNISONE + THALIDOMIDE IN INDUCTION THERAPY FOR MULTIPLE MYELOMA IN ELDERLY PATIENTS: FIRST INTERIM RESULTS OF THE DUTCH COOPERATIVE GROUP HOVON
P. Wijermans, M. Schaafsma, Y. Van Norden, R. Ammerlaan,
P. Sonneveld, S. Wittebol, H. Sinnige, P. Huijgens, M. van Marwijk Kooy, R. van der Griend (Haga Hospital, The Hague, The Netherlands)

11:30 – 11:45
0441 OVERALL SURVIVAL WITH DEXAMETHASONE IN PHASE III MULTIPLE MYELOMA TRIALS AFTER ADJUSTMENT FOR CROSS-OVER TO LENALIDOMIDE
G. Morgan, K. Ishak, B. Deniz, T. Drayson, M. Dimopoulos, M. Weber,
M. Augustson, J. Child, R. Knight, G. Begum, A. Dunn, A. Shearer,
J. Caro (The Royal Marsden NHS Foundation Trust & The Institute of Cancer Research, Surrey, United Kingdom)

[

Print view ]